Patient Information    |  Important Safety Information  |  For Healthcare Professionals  |  Text Size A A A

References

  1. TYKERB [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
  2. Targeted cancer therapies: questions and answers. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/
    factsheet/Therapy/targeted    . Accessed June 5, 2007.
  3. Vlahovic G, Crawford J. Activation of tyrosine kinases in cancer. Oncologist. 2003;8(6):531-538.
  4. AACR cancer concepts: HER2. American Association for Cancer Research Web site. Available at: http://www.aacr.org/home/public--media/for-the-media/fact-sheets/cancer-concepts/her2.aspx. Accessed June 1, 2007.
  5. Diarrhea. American Cancer Society Web site. Available at: http://www.cancer.org/docroot/MBC/
    content/MBC_2_3X_Diarrhea.asp    . Accessed August 30, 2007.
  6. Data on file. GlaxoSmithKline.
  7. Gastrointestinal complications (PDQ®): Diarrhea. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/
    gastrointestinalcomplications/Patient/page6    . Accessed
    May 24, 2007.
  8. Diarrhea and chemotherapy. Chemocare.com Web site. Available at: http://www.chemocare.com/managing/
    diarrhea_and_chemotherapy.asp    . Accessed May 31, 2007.
  9. Coping with side effects. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/chemotherapy-and-you/page4. Accessed June 5, 2007.
  10. Pérez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005 May;10(5):345-356.
  11. Skin reactions to targeted treatments. People Living With Cancer Web site. Available at:
    http://www.plwc.org/portal/site/PLWC/menuitem.
    Accessed May 24, 2007.
  12. Hand-foot syndrome. Chemocare.com Web site. Available at: http://www.chemocare.com/managing/handfoot_syndrome.asp. Accessed August 30, 2007.
  13. Eating hints for cancer patients: before, during, and after treatment. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/eatinghints/allpages. Accessed August 30, 2007.
  14. Nausea, vomiting, and chemotherapy. Chemocare.com Web site. Available at: http://www.chemocare.com/managing/
    nausea_vomiting__chemotherapy.asp    . Accessed
    August 30, 2007.
  15. About cancer fatigue. Cancersymptoms.org Web site. Available at: http://www.cancersymptoms.org/fatigue/key.shtml. Accessed August 31, 2007.
  16. Fatigue and cancer care. Chemocare.com Web site. Available at: http://www.chemocare.com/managing/
    fatigue_and_cancer_fatigue.asp    . Accessed August 31, 2007.
  17. Xeloda [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2006.
  18. Does the cancer have genes that are not normal? (HER-2 status). Breastcancer.org Web site. Available at: http://www.breastcancer.org/her2_status.html. Accessed
    May 24, 2006.
  19. Breast cancer overview. People Living With Cancer Web site. Available at: http://www.plwc.org/portal/site/PLWC/
    menuitem.6067beb2271039bcfd748f68ee37a01d/?
    vgnextoid=6ec6ea7105daa010Vgn
    VCM100000ed730ad1RCRD&vgnextfmt=cancer    . Accessed
    July 13, 2007.
  20. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18.
  21. Metastatic cancer: questions and answers. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic. Accessed June 1, 2007.
  22. Advanced (metastatic) breast cancer. Imaginis Corporation Web site. Available at: http://www.imaginis.com/breasthealth/metastatic.asp. Accessed June 1, 2007.
  23. What is cancer? American Cancer Society Web site. Available at: http://www.cancer.org/docroot/
    CRI/content/CRI_2_4_1x_What_Is_Cancer.asp?sitearea=    . Accessed June 1, 2007.
  24. Overview: breast cancer: what is breast cancer? American Cancer Society Web site. Available at: http://www.cancer.org/docroot/CRI/content/
    CRI_2_2_1X_What_is_breast_cancer_5.asp?sitearea=    . Accessed June 1, 2007.
  25. Overview: breast cancer: what causes breast cancer? American Cancer Society Web site. Available at: http://www.cancer.org/docroot/CRI/content/
    CRI_2_2_2X_What_causes_breast_cancer_5.asp?sitearea=    . Accessed June 1, 2007.
  26. Breast cancer treatment guidelines for patients. American Cancer Society Web site. Available at: http://www.cancer.org/downloads/CRI/Breast_VIII.pdf. Accessed June 4, 2005.
  27. Detailed guide: breast cancer: hormone therapy. American Cancer Society Web site. Available at: http://www.cancer.org/docroot/CRI/content/
    CRI_2_4_4X_Hormone_Therapy_5.asp?sitearea=    . Accessed June 5, 2007.
  28. Medical dictionary. U.S. Library of Medicine Web site. Available at: http://www.nlm.nih.gov/medlineplus/mplusdictionary.html. Accessed July 13, 2007.
  29. Understanding chemotherapy. National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/
    chemotherapy-and-you/page2    . Accessed June 5, 2007.
  30. Nutrition in cancer care (PDQ®). National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/
    pdq/supportivecare/nutrition    . Accessed July 13, 2007.
  31. Fatigue (PDQ®). National Cancer Institute Web site. Available at: http://www.cancer.gov/cancertopics/pdq/supportivecare/
    fatigue/patient    . Accessed July 13, 2007.
  32. Glossary. American Cancer Society Web site. Available at: http://www.cancer.org/docroot/MBC/content/
    MBC_6_2X_Nutrtion_Glossary.asp    . Accessed March 1, 2007.
  33. Medical dictionary. U.S. National Library of Medicine Web site. Available at: http://www.nlm.nih.gov/medlineplus/mplusdictionary.html. Accessed March 1, 2007.
  34. Dictionary of cancer terms. National Cancer Institute Web site. Available at: http://www.cancer.gov/dictionary. Accessed
    March 1, 2007.
  35. How is breast cancer staged? American Cancer Society Web site. Available at: http://www.cancer.org/docroot/CRI/
    content/CRI_2_4_3X_How_is_breast_cancer_staged_5.asp    . Accessed March 1, 2007.


Check out GlaxoSmithKline's Tykerb® CARES support program to help patients and the healthcare providers who treat them.


Questions about treatment with TYKERB?
Ask the Experts

Get the latest information
from www.TYKERB.com


Indication

TYKERB is indicated in combination with Xeloda® (capecitabine) for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and Herceptin® (trastuzumab).

Important Safety Information

Before taking TYKERB, tell your doctor if you have heart problems. As with other treatments for HER2-positive advanced or metastatic breast cancer, there have been reports of changes in how the heart pumps blood through the body and how the heart beats. Call your doctor right away if you are short of breath, have rapid heartbeats (palpitations), or feel very tired.

Tell your doctor if you have liver problems. People who have liver problems may not be able to process TYKERB well, so you may need a lower dose of TYKERB.

Some people taking TYKERB have reported diarrhea. In some cases, diarrhea can be severe. Call your doctor right away if you have diarrhea. It is important to manage diarrhea with medicine as soon as it begins. Severe diarrhea may need to be treated with electrolytes and fluids given by mouth or by vein. Treatment with TYKERB may have to be delayed for a while or stopped completely.

If you have a dry cough or have shortness of breath, talk with your doctor. These may be signs of inflammation in the lungs.

Women should not become pregnant when taking TYKERB because the unborn baby may be harmed.

The most common side effects reported by patients taking TYKERB and Xeloda were diarrhea; vomiting; feeling sick to your stomach (nausea); feeling tired; red, painful hands and feet; and rash.

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines and herbal and dietary supplements.

Because TYKERB is currently indicated to be taken with another medicine called Xeloda, be sure to talk with your doctor about any medicines and supplements that should be avoided when taking Xeloda.

Please see complete US Prescribing Information for TYKERB.

Herceptin is a registered trademark of Genentech, Inc.
Xeloda is a registered trademark of Roche Laboratories Inc.

Photos are for illustrative purposes only.